Close

BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018

Legislation will strengthen pipeline of medical countermeasures against serious public health threats   Washington, DC (September 25, 2018) – The Biotechnology Innovation Organization (BIO) today applauds the House of Representatives for passing the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (H.R. 6378). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS).  

BIO Applauds Release of New National Biodefense Strategy

“I applaud the Administration for recognizing the importance of strengthening our national biodefense and preparedness efforts. Our nation continues to face a wide range of biological threats, and this strategy is an important step in the right direction."

BIO Applauds Advancement of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018

Legislation would strengthen the pipeline and stockpile of medical countermeasures vital to our nation’s safety and defense

Rick Bright, Ph.D. (BARDA) at the 2017 BIO International Convention

Mike Huckman interviews Rick Bright, Ph.D. (BARDA) at the 2017 BIO International Convention Buzz Center.

BIO submits comments to Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models

The Biotechnology Innovation Organization appreciates the opportunity to offer comments to the final rule Medicare Program; Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models.

BIO Comments on the National Quality Forum Health and Wellbeing 2015-2017 Report

BIO appreciates the opportunity to comment on the National Quality Forum (NQF) Health and Wellbeing 2015-2017 report.

BIO Applauds Senate Passage of the 21st Century Cures Act

Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:

BIO Applauds House Passage of the 21st Century Cures Act

Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

Vaccines: 2008 Draft Strategic National Vaccine Plan

The National Vaccine Program was established in 1986 to achieve optimal prevention of infectious diseases through immunization and optimal prevention of adverse reactions to vaccines.

Vaccines: 2009-H1N1 Influenza NVAC Vaccination Program Financing

This Report contains NVAC recommendations based on the Working Group’s findings and conclusions, and includes recommendations developed by the NVAC Adolescent Working Group. It takes into account public comments and extensive stakeholder input received. The overall goal of the Report is to ensure that all children and adolescents have access to all routinely recommended vaccinations without financial barriers.